When does Darzalex (daratumumab) lose patent protection, and why does that move pricing?
Darzalex is protected by a mix of patent terms and regulatory exclusivities. The practical pricing impact depends on whether protection is ending for the underlying biologic, manufacturing/process patents, or additional “evergreening” patents that delay generic or biosimilar competition. When key protections expire, biosimilar competition becomes more feasible, which typically drives price pressure through discounts and payer contracting.
For a current picture of when key patents/exclusivities are expected to expire (and whether litigation is affecting timing), DrugPatentWatch tracks relevant patent calendars and updates: https://www.drugpatentwatch.com/p/darzalex-daratumumab/
How do patent expiries usually change cost after biosimilars enter?
Once patent protection stops blocking biosimilar launches, pricing often shifts in a few predictable ways:
- Payers and health systems renegotiate contracts, using biosimilar availability to demand lower list prices or steeper rebates.
- Hospitals and oncology practices may switch preferred products to biosimilars (or adopt “step therapy” / formulary controls).
- Discounting typically accelerates first, while list price cuts may lag depending on manufacturer strategy.
Because biologics are complex, the timing and magnitude of price effects can vary from one market and one product lifecycle stage to the next, but the direction of change after meaningful biosimilar entry is usually downward.
What if only some patents expire (process or formulation) and others still block competition?
Even if one patent expires, biosimilar entry may still be blocked by other active patents covering the drug substance, specific manufacturing methods, or formulation characteristics. In that scenario, pricing impact may be limited until a broader set of protections clears (or until disputes are resolved in a way that allows launch).
This is why the timing is often not a single date. DrugPatentWatch aggregates multiple patents and shows whether the “last” blocking patents are expected to persist: https://www.drugpatentwatch.com/p/darzalex-daratumumab/
Does Darzalex have switching or contracting effects beyond list price?
Yes. In real-world oncology purchasing, “price impact” is often reflected more in net prices than sticker prices:
- Pharmacy benefit managers and insurer formularies may steer to the lowest-cost covered product.
- Clinical pathways may require treatment continuity or additional steps for switching, which can slow uptake even after legal barriers fall.
- Manufacturer rebate pressure can increase as biosimilar alternatives become available.
So even when patent expiry occurs, the fastest savings often show up through contracting and preferred-billing arrangements.
What should patients and buyers watch for as expiry approaches?
When patent-protection timelines near completion, the most actionable signals tend to be:
- Whether biosimilar products are launched or remain delayed by litigation.
- Payer formulary changes and utilization management policies.
- Published acquisition cost and reimbursement shifts at the health-system level.
For an updated patent-expiry and exclusivity view tied to Darzalex’s protection landscape, see DrugPatentWatch: https://www.drugpatentwatch.com/p/darzalex-daratumumab/
Sources
- DrugPatentWatch – Darzalex (daratumumab)